Cargando…

Evaluating the Response and Safety of Inactivated COVID-19 Vaccines in Liver Transplant Recipients

PURPOSE: To evaluate the response and safety of an inactivated vaccine (Sinovac Life Sciences Co., Ltd., Beijing, China) for coronavirus disease 2019 (COVID-19) in liver transplant (LTx) recipients from China. PATIENTS AND METHODS: Thirty-five recipients post LTx from the First Affiliated Hospital o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Zhen-Hua, Jin, Ping-Bo, Chen, Di-Yu, Chen, Zhi-Yun, Li, Zhi-Wei, Wu, Jie, Lou, Bin, Zhang, Bao-Shan, Zhang, Lin, Zhang, Wei, Liang, Ting-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112169/
https://www.ncbi.nlm.nih.gov/pubmed/35592105
http://dx.doi.org/10.2147/IDR.S359919
_version_ 1784709364742881280
author Tu, Zhen-Hua
Jin, Ping-Bo
Chen, Di-Yu
Chen, Zhi-Yun
Li, Zhi-Wei
Wu, Jie
Lou, Bin
Zhang, Bao-Shan
Zhang, Lin
Zhang, Wei
Liang, Ting-Bo
author_facet Tu, Zhen-Hua
Jin, Ping-Bo
Chen, Di-Yu
Chen, Zhi-Yun
Li, Zhi-Wei
Wu, Jie
Lou, Bin
Zhang, Bao-Shan
Zhang, Lin
Zhang, Wei
Liang, Ting-Bo
author_sort Tu, Zhen-Hua
collection PubMed
description PURPOSE: To evaluate the response and safety of an inactivated vaccine (Sinovac Life Sciences Co., Ltd., Beijing, China) for coronavirus disease 2019 (COVID-19) in liver transplant (LTx) recipients from China. PATIENTS AND METHODS: Thirty-five recipients post LTx from the First Affiliated Hospital of Zhejiang University School of Medicine who received inactivated vaccine from June to October 2021 were screened. Information regarding vaccine side effects and clinical data were collected. RESULTS: Thirty-five LTx recipients were enrolled, with a mean age of 46 years, and most patients were male (30, 85.71%). All the participants had a negative history of COVID-19 infection. Predictors for negative response in the recipients were interleukin-2 receptor (IL-2R) induction during LTx, shorter time post LTx and application of a derivative from mycophenolate acid (MPA). No serious adverse events were observed during the progress of vaccination or after the vaccination. CONCLUSION: LTx recipients have a substantially partial immunological response to the inactivated vaccine for COVID-19. IL-2R induction during LTx, a shorter time post LTx and the application of a derivative from MPA seem to be predictors for a negative serological immunoglobulin G (IgG) antibody response in recipients. The findings require booster vaccination in these LTx recipients.
format Online
Article
Text
id pubmed-9112169
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-91121692022-05-18 Evaluating the Response and Safety of Inactivated COVID-19 Vaccines in Liver Transplant Recipients Tu, Zhen-Hua Jin, Ping-Bo Chen, Di-Yu Chen, Zhi-Yun Li, Zhi-Wei Wu, Jie Lou, Bin Zhang, Bao-Shan Zhang, Lin Zhang, Wei Liang, Ting-Bo Infect Drug Resist Original Research PURPOSE: To evaluate the response and safety of an inactivated vaccine (Sinovac Life Sciences Co., Ltd., Beijing, China) for coronavirus disease 2019 (COVID-19) in liver transplant (LTx) recipients from China. PATIENTS AND METHODS: Thirty-five recipients post LTx from the First Affiliated Hospital of Zhejiang University School of Medicine who received inactivated vaccine from June to October 2021 were screened. Information regarding vaccine side effects and clinical data were collected. RESULTS: Thirty-five LTx recipients were enrolled, with a mean age of 46 years, and most patients were male (30, 85.71%). All the participants had a negative history of COVID-19 infection. Predictors for negative response in the recipients were interleukin-2 receptor (IL-2R) induction during LTx, shorter time post LTx and application of a derivative from mycophenolate acid (MPA). No serious adverse events were observed during the progress of vaccination or after the vaccination. CONCLUSION: LTx recipients have a substantially partial immunological response to the inactivated vaccine for COVID-19. IL-2R induction during LTx, a shorter time post LTx and the application of a derivative from MPA seem to be predictors for a negative serological immunoglobulin G (IgG) antibody response in recipients. The findings require booster vaccination in these LTx recipients. Dove 2022-05-12 /pmc/articles/PMC9112169/ /pubmed/35592105 http://dx.doi.org/10.2147/IDR.S359919 Text en © 2022 Tu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Tu, Zhen-Hua
Jin, Ping-Bo
Chen, Di-Yu
Chen, Zhi-Yun
Li, Zhi-Wei
Wu, Jie
Lou, Bin
Zhang, Bao-Shan
Zhang, Lin
Zhang, Wei
Liang, Ting-Bo
Evaluating the Response and Safety of Inactivated COVID-19 Vaccines in Liver Transplant Recipients
title Evaluating the Response and Safety of Inactivated COVID-19 Vaccines in Liver Transplant Recipients
title_full Evaluating the Response and Safety of Inactivated COVID-19 Vaccines in Liver Transplant Recipients
title_fullStr Evaluating the Response and Safety of Inactivated COVID-19 Vaccines in Liver Transplant Recipients
title_full_unstemmed Evaluating the Response and Safety of Inactivated COVID-19 Vaccines in Liver Transplant Recipients
title_short Evaluating the Response and Safety of Inactivated COVID-19 Vaccines in Liver Transplant Recipients
title_sort evaluating the response and safety of inactivated covid-19 vaccines in liver transplant recipients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112169/
https://www.ncbi.nlm.nih.gov/pubmed/35592105
http://dx.doi.org/10.2147/IDR.S359919
work_keys_str_mv AT tuzhenhua evaluatingtheresponseandsafetyofinactivatedcovid19vaccinesinlivertransplantrecipients
AT jinpingbo evaluatingtheresponseandsafetyofinactivatedcovid19vaccinesinlivertransplantrecipients
AT chendiyu evaluatingtheresponseandsafetyofinactivatedcovid19vaccinesinlivertransplantrecipients
AT chenzhiyun evaluatingtheresponseandsafetyofinactivatedcovid19vaccinesinlivertransplantrecipients
AT lizhiwei evaluatingtheresponseandsafetyofinactivatedcovid19vaccinesinlivertransplantrecipients
AT wujie evaluatingtheresponseandsafetyofinactivatedcovid19vaccinesinlivertransplantrecipients
AT loubin evaluatingtheresponseandsafetyofinactivatedcovid19vaccinesinlivertransplantrecipients
AT zhangbaoshan evaluatingtheresponseandsafetyofinactivatedcovid19vaccinesinlivertransplantrecipients
AT zhanglin evaluatingtheresponseandsafetyofinactivatedcovid19vaccinesinlivertransplantrecipients
AT zhangwei evaluatingtheresponseandsafetyofinactivatedcovid19vaccinesinlivertransplantrecipients
AT liangtingbo evaluatingtheresponseandsafetyofinactivatedcovid19vaccinesinlivertransplantrecipients